Equities

COSCIENS Biopharma Inc

COSCIENS Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)5.56
  • Today's Change0.000 / 0.00%
  • Shares traded95.00
  • 1 Year change-61.60%
  • Beta2.2758
Data delayed at least 15 minutes, as of Sep 19 2024 18:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects COSCIENS Biopharma Inc share price to fall to 4.00 in the next year from the last price of 5.56.
High-28.1%4.00
Med-28.1%4.00
Low-28.1%4.00

Earnings history & estimates in USD

Earnings forecasts are not available for COSCIENS Biopharma Inc. On Aug 13, 2024, COSCIENS Biopharma Inc reported 2nd quarter 2024 losses of -- per share.
Average growth rate-49.97%
COSCIENS Biopharma Inc reported annual 2023 losses of -13.64 per share on Mar 27, 2024.
Average growth rate-42.45%
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Aeterna Zentaris Inc..
Average growth rate+1,916.73%
Aeterna Zentaris Inc. had revenues for the full year 2023 of 4.50m. This was 20.25% below the prior year's results.
Average growth rate+86.52%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.